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Abstract
Background: Evidence-informed policymaking has been promoted as a means of ensuring better outcomes.
However, what counts as evidence in policymaking lies within a spectrum of expert knowledge and scientifically
generated information. Since not all forms of evidence share an equal validity or weighting for policymakers, it is
important to understand the key factors that influence their preferences for different types of evidence in policy
and strategy development.
Method: A retrospective study was carried out at the national level in Nigeria using a case-study approach to
examine the Nigerian Integrated Maternal Newborn and Child Health (IMNCH) strategy. Two frameworks were
used for conceptualization and data analysis, namely (1) to analyse the role of evidence in policymaking and (2)
the policy triangle. They were used to explore the key contextual and participatory influences on choice of
evidence in developing the IMNCH strategy. Data was collected through review of relevant national documents
and in-depth interviews of purposively selected key policy and strategic decision makers. Thematic analysis was
applied to generate information from collected data.
Results: The breadth of evidence used was wide, ranging from expert opinions to systematic reviews. The choice
of different types of evidence was found to overlap across actor categories. Key influences over actors’ choice of
evidence were: (1) perceived robustness of evidence – comprehensive, representative, recent, scientifically sound;
(2) roles in evidence process, i.e. their degree and level of participation in evidence generation and dissemination,
with regards to their role in the policy process; and (3) contextual factors such as global agenda and influence,
timeline for strategy development, availability of resources for evidence generation, and lessons learnt from previous
unsuccessful policies/plans.
Conclusion: Actors’ preferences for different types of evidence for policy are influenced not only by the characteristics
of evidence itself, but on actors’ roles in the evidence process, their power to influence the policy, and the context in
which evidence is used.
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Background
It is indeed recognized that policymaking is a complex
process [1] and health policies are constructed and brought
alive by actors through the meaning they attach to their
experiences [2]. Evidence-informed policymaking has been
promoted as a means of ensuring better outcomes through
rational analysis and use of available evidence [3]. This
implies a shift from opinion-based decision-making to
decision-making based on integration of the best available
external evidence from systematic reviews with valid expe-
riences and reliable judgments of experts [4]. The depth
and quality of information used by policy actors for policy-
making is argued to have an influence on how effective
policies are [5].
Evidence has the potential to influence policy pro-
cesses at different stages and different types of evidence
might be needed for different stages of policy develop-
ment [3]. At the agenda setting stage, evidence is needed
to identify a new problem or build on the magnitude of
an existing one, and the key factors here are credibility
of the evidence and the way it is communicated to the
policymakers. The policy formulation stage requires evi-
dence for the understanding of a specific situation and
the comprehension of different options, and the quantity
and credibility of available evidence are important fac-
tors to consider [3]. For the policy implementation stage,
the focus is on operational evidence to improve effect-
iveness; therefore, practicality and context relevance are
important considerations in choice of evidence [3].
The emphasis placed on evidence-informed policy-
making is as a result of the understanding that rational
analysis and use of available evidence better informs pol-
icy decisions. Evidence is needed to understand the pol-
icy environment, appraise the likely effects of policy
changes to enable choice, and demonstrate linkages be-
tween strategic direction, intended outcomes and policy
objectives [6]. Using evidence generated from the groups
of people affected by policy is important in the policy
formulation process since policies are made to shape
and manage people’s behaviour. However, not all forms
of evidence lend themselves to use in decision making
[7]. Policy actors provide varying degrees of preference
for and use of different types of evidence in policy de-
velopment. Since not all forms of evidence share an
equal validity or weighting for policymakers, it is im-
portant to understand what types of evidence they find
useful for decision making.
What counts as evidence in policymaking is conten-
tious and has been described to include expert know-
ledge, published research and output from economic
and statistical modelling, outcomes from stakeholder
consultations, and previous policy evaluations, among
other [8]. Drawing from the works of Newman et al. [5]
and Marston and Watts [9], the authors define evidence
as information – both formal and informal – that can be
used in supporting (or otherwise) a conclusion or indi-
cating whether an assumption or proposition is true or
valid. Formal evidence here would include peer-reviewed
research reports and health management information
system and statistical data from surveys. Informal evi-
dence includes expert knowledge and experiences as well
as outcomes of stakeholder consultations. Policymakers,
in sorting information to be used, are required to make
complex judgments about institutional interests repre-
sented in the policymaking process [9], while remaining
sensitive to what is most suited in the circumstance/con-
text. Therefore, the questions that policymakers ask in
order to make decisions go beyond what merely works;
they also address how it will work in a particular setting,
what it will cost and the consequences of implementa-
tion [10].
The aim of this study was to understand factors that
influenced the use of evidence in the development of
the Nigerian Integrated Maternal Newborn and Child
Health (IMNCH) strategy. We examined actors’ roles
in developing the IMNCH strategy, their perceptions of
evidence and its use in developing the strategy and the
key contextual influences on their preferences for and
use of evidence in developing the strategy. This paper
contributes to existing knowledge on the implications
of context and actors’ roles in policy development on
their degree of support for and use of evidence in policy
development.
Description of context for the development of the
Nigerian IMNCH strategy
Nigeria contributes about 10% of the global total of
under-5 and maternal mortality, the second largest in
the world [11]. About 2,300 children under 5 years of age
and 145 women of child bearing age die every day due to
preventable diseases and pregnancy-related causes [12].
At the time of developing the IMNCH strategy, Nigeria
was making slow progress towards meeting the targets of
Millennium Development Goals (MDGs) 4 and 5 [13, 14].
The Global Partnership for Maternal, Newborn and
Child Health (PMNCH) was formed with the specific
aim to support the scale-up of high-impact low-cost in-
terventions in six countries, including Nigeria. Following
a Partnership Grant from PMNCH in 2006, the Federal
Ministry of Health was tasked with the responsibility of
coordinating actions and partners in accelerating the
reduction in maternal, newborn and child mortality
[15], and in collaboration with some of these partners
(including WHO, UNICEF, UNFPA) developed the
IMNCH strategy [12].
The overall objective of the IMNCH strategy is to
reduce maternal, newborn and child morbidity and mor-
tality, in line with MDGs 4 and 5, through improved
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access to quality services, adequate funding and manage-
ment of MNCH services, strengthened community par-
ticipation and monitoring and evaluation systems, and
sustained partnerships for implementation. The strategy
is based on the principles of continuum of care and a
seamless linkage between family, community and health
facilities, coherent integration of priority interventions
into the health system, rights-based planning, equitable
access, multisector collaboration, and effective partner-




The conceptual framework for the study was adapted
from the EVAL-health conceptual framework for asses-
sing the role of evidence in policy development [16]
and the policy analysis triangle by Walt and Gilson
[17]. This framework provides guidance for under-
standing key influences on the role of evidence in
policymaking and guides the analysis of the role of
policy actors and context on evidence use to develop
the IMNCH strategy (Fig. 1). For the purpose of this
study, evidence was defined as information – both for-
mal and informal – that can be used in supporting (or
otherwise) a conclusion or indicating whether an as-
sumption or proposition is true or valid. Formal evi-
dence here would include peer-reviewed research,
reports, and health management information system
and statistical data. Informal evidence includes expert
knowledge and experiences as well as outcomes of
stakeholder consultations.
The interplay between evidence and policy processes
influences the role of evidence in policymaking; and pol-
icy actors, through the roles they play in both processes,
and their interests or agenda, determine this interplay.
All of these occur within a wider context of national,
international and global influences. The degree to which
evidence informs policy is initiated and facilitated by
policy actors (communities and networks). These varied
actors have different roles in evidence and policy pro-
cesses, and their specific priorities and capacities could
influence their perceptions of what makes ‘robust’ evi-
dence. This ultimately affects their preferences for and use
of evidence for policy decisions. Actors will also have
relationships (policy networks, alliances and communities)
between themselves, which can make them more or less
powerful within the policy arena and affect their ability to
influence policy through evidence use. These networks
could also influence their perceptions of robust evidence.
The ideology, values, belief system and organisational
culture of decision making also characterise policy actors
and influence their perception of robust evidence. Actors
who influence policies through financing of health ser-
vices, exercise enough power through their support in
determining issues that are legitimate and feasible enough
to be taken up on the policy agenda [18, 19].
Study area
This study was conducted at the Federal Capital Territory
of Nigeria, where all national policies are made. Nigeria is a
country in West Africa with a population of approximately
170 million people. The 2013 Nigeria Demographic and
Fig. 1 Conceptual framework for analysing key influences over policy actors’ preference for and use of evidence in policy development [16]
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Health Survey reported a maternal mortality ratio of 576/
100,000 live births, an infant mortality rate of 69/1000 live
births and an under-5 mortality rate of 128/1000 live
births. The health system is organized into three levels,
namely tertiary, secondary and primary, which provide
varying degrees of maternal and child health services.
The primary level provides normal delivery services,
basic emergency obstetric care, immunization services
and treatment of common childhood illnesses. Added
to these, the secondary level offers comprehensive
emergency obstetric care services, management of com-
plications of common childhood illnesses, and in-
patient services. Specialized care is provided at tertiary
levels of care.
Study design
This was a retrospective study that covers what hap-
pened from September 2006, when development of the
IMNCH strategy started, until March 2007, when it was
presented to stakeholders for validation. Drawing on the
IMNCH strategy development in Nigeria as a case study,
we explored the implications of actors’ roles and policy
context on their preference for and use of evidence in
policy development. The IMNCH strategy was purpos-
ively selected for the following reasons: (1) there exists a
clear written strategy statement; (2) it is a relatively new
strategy document that was developed in 2007 (to re-
duce recall bias); (3) it concerns a national priority area
of health; and (4) there are available national and inter-
national data on maternal and child health.
Data collection
Data was collected using government documents review
and in-depth interviews of key respondents to examine
(1) the roles of different actors in the development of
the IMNCH strategy, (2) actors’ preferences for and use
of evidence in the strategy development, and (3) the key
positional and contextual influences on their preferences
for and use of certain types of evidence in developing
the IMNCH strategy.
Relevant government documents that were reviewed are
the IMNCH strategic plan; Workshop summary on redu-
cing maternal and infant mortality in Nigeria; NSHDP
2009–2015; Communication strategy for Community
IMNCH; Report of the Hon. Minister for Health’s presen-
tation on MNCH in Nigeria. Abstraction of relevant data
from documents was performed using a template.
The selection of key respondents for the in-depth in-
terviews was informed first from initial review of the
strategy document, followed by consultation with key
stakeholders and sequential referral from respondents
during data collection. They were purposively selected
to represent key policymaker/influencer groups such
as: government officials (5 key informants (KIs)),
development partners (2 KIs), academia/professional
group (1 KI), health workers (1 KI), and civil society (1
KI). A total of 10 KIs were interviewed, nine through face-
to-face interviews and one by telephone interview. Re-
spondents’ preference for and use of evidence was ex-
plored by asking them what they understood evidence to
mean; what they considered to be robust evidence for pol-
icymaking and their reasons for saying so; and what types
of evidence they felt were most useful for developing the
IMNCH strategy. Their roles in strategy development and
evidence process were explored.
Data management and ethical approval
Digital recordings of interviews were transcribed in English.
Transcripts were managed and coded in NVivo 8 using a
combined thematic and framework approach. Coded data
were organized into tables and charts according to major
themes based on the study objectives, and other themes
that emerged from the interviews.
Ethical approval was obtained from the University of
Nigeria Teaching Hospital Ethical Review Board before
the commencement of the primary data collection. The
conventional ethical considerations for conducting re-
search (preserving anonymity, ensuring confidentiality
and obtaining informed consent) were complied with.
Results
Actors involved in IMNCH strategy development
Different groups of actors were involved in developing
the IMNCH strategy and they played varied roles in both
the strategy development and evidence process – gener-
ation, dissemination and use. Table 1 summarizes these
actors and their roles in the strategy development and
Table 2 summarizes their roles in evidence generation,
dissemination and use. The categories of actors that
were identified by different respondents to have been in-
volved in developing the IMNCH strategy included (1)
public policy elites and government officials; (2) develop-
ment partners and donor organisations; (3) professional
groups; and (4) civil society groups and non-government
organisations: “All stake holders were really involved in
the policy process ranging from government where we
involved the states, to development partners and civil
society organization […] and professional associations
like SOGON” – (Public policy elite).
The public policy elite category includes high level
government officers in the Ministry of Health like the
Permanent Secretary, unit and department heads; politi-
cal office holders like the Minister for Health and mem-
bers of board of directors in the Ministry of Health; and
National Council on Health and Federal Executive Com-
mittee. The development partner category includes the
three UN agencies involved in maternal and child health
in Nigeria – WHO, UNICEF, UNFPA, which advise and
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inform policymakers on options, their alternatives and
the resultant effects. The non-governmental and civil so-
ciety groups includes not-for-profit and for-profit orga-
nisations and corporations who have a special interest in
maternal and child health issues; they often represent
public interest. The professional group category is a col-
lection of professional groups involved in maternal and
child health (MCH) such as the Society of Gynaecolo-
gists and Obstetricians of Nigeria (SOGON), the Confer-
ence of Paediatricians Association of Nigeria, and the
National Association of Nurses and Midwives: “In the
Federal Ministry of Health, the lead department was
Family Health, and then we have the development part-
ners especially the UNH4, and professional associations
like SOGON” – (Government official); “Paediatric associ-
ation of Nigeria was involved; National Association of
Nurses and Midwives were involved” – (Civil Society Or-
ganisation (CSO)). Some category of actors, such as
healthcare providers and academia, were not specifically
mentioned. However, they are members of professional
associations and often constitute the technical working
groups in policy development, and in that capacity con-
tribute in developing policies and strategies.
Actors’ influence in the IMNCH strategy development
process
An analysis of the influence of actors who were involved
in developing the IMNCH strategy in both strategy
development and evidence processes as perceived by
other actors is summarized in Table 3. Some actors were
perceived to have played more prominent roles in the
strategy development and were mentioned more often
than others. Actors in the Ministry of Health were iden-
tified to have spearheaded the process with significant
support from development partners in UN agencies who
provided funding for the process. Some quotes are, “The
idea came from the Federal Ministry of Health and was
spearheaded by them” (Policy elite); “most of what we
did was funded by partners” (Government official); “The
partnership for MNCH had mobilized a lot of resources
also and we could not have done it without that” (Policy
elite). Another group of policy elites, the Federal
Table 1 Types of actors involved in developing the Integrated Maternal Newborn and Child Health (IMNCH) strategy and their roles
Actor categories Types of actors involved Roles in strategy development
Public policymakers and government
officials
1) High level government officials in the Federal
Ministry of Health such as:
• Mandate to make policies (directional power)
- Permanent secretary • Endorsement and approval of policies
- Deputy Director of Reproductive Health
- Director of Planning, Research and Statistics
2) Political office holders such as:
- Minister for Health
3) Approval bodies such as:
- National Council on Health (NCoH)
-Federal executive council (FEC)
- Legislators
Development partners and donor
agencies
United Nations Children’s Fund (UNICEF) • Provided technical assistance/input – advise and
inform policymakers on options, their alternatives
and the resultant effectsWorld Health Organization (WHO)
United Nation Fund for Population (UNFPA) • Funded major aspects of the policy development
Partnership for Maternal and Child Health (PMNCH)
Professional groups Society for Obstetricians and Gynecologists of
Nigeria (SOGON)
Technical inputs through membership of technical
working groups for developing the IMNCH strategya
Conference of Paediatricians Association of Nigeria
(PANCOF)




Management Sciences for Health (MSH) Advocacy and lobbying for inclusion of priority
maternal and child health needs on the policy agenda
and equitable distribution of resources and servicesUN Committee on Elimination of Discrimination
Against Women (CEDAW)
UN Committee on the Rights of the Child (CRC)
aAlthough majority of the key informants had this opinion, one key informant differed (Details are in description of Table 1 in the text)
Mbachu et al. Health Research Policy and Systems  (2016) 14:27 Page 5 of 11
Executive Council and the National Council on Health,
who may not have largely participated in the strategy
process, appeared to play a determinant role on whether
the strategy would see the light of day. Without their ap-
proval and endorsement, there would not have been an
IMNCH strategy. Their influence on policies/strategies
developed in the country is very high given the role that
they play.
The level of influence of the international community
in the policy process was perceived by representatives of
CSOs and professional groups to be very high: “whether
the international community came and influenced what
was happening in Nigeria, nobody wants to say that, be-
cause the extent which they could influence was based on
the funding they could provide. I want to tell you that
the federal government, on its own, did not launch that
program, the fund was from international community”
(Professional).
Respondents’ perceptions of level of involvement and
degree of participation of actors in the policy process
differed. While some government officials and policy-
makers felt that all groups of actors participated fully in
the policy development, representatives of professional/
health worker groups felt their involvement was limited
to the strategy roll-out stage, and with superficial partici-
pation at that. There was a feeling that the inputs made
by the CSOs and professional groups were not consid-
ered or taken into account: “[….] people were asked to
say their views about how things were going and those
things were never taken into account” (Professional).
Table 2 Role of actors in evidence process (generation, dissemination and use) for the Integrated Maternal Newborn and Child
Health (IMNCH) strategy
Actor types Roles in evidence generation Roles in evidence dissemination Roles in evidence use
Public policymakers and
government officials
Supervised the collation of evidence
from surveys (DHS) and for the
situation analysis (SITAN)
Distributed survey and SITAN
reports to other stakeholders
Used all available evidence to:
1) justify the need for IMNCH
strategy
2) determine interventions to
be included in the strategy
Development partners and
donor agencies
Funding and technical support for: Distributed MBB tool and Lancet
series to public policymakers and
technical experts/consultants
No clearly stated role
in evidence use
1) situation analysis (SITAN) and
DHS
2) developing the marginal
budgeting for bottleneck
(MBB) tool
Provided funding to the
Federal Ministry of Health to
assist in evidence dissemination
Recommended the Lancet series on
low-cost effective interventions for
maternal and child health (MCH)
Professional groups as members of
technical working group
Scoped for and collated published
research articles and unpublished
technical reports of maternal and
child mortality and evaluation of
MCH interventions
No stated role in disseminating
evidence for the IMNCH strategy
Decided on which evidence was




No stated role in the whole
evidence process
Table 3 Respondents’ perception of actors’ capacity to influence the Integrated Maternal Newborn and Child Health (IMNCH)
strategy development
Types of actors Types and levels of actors’ influence on the IMNCH strategy development Types of influence
Directional Funding Technical/Advisory Discretionary/Implementation Advocacy
Public policy elites and
Government officials
High Medium Medium Low Low Levels of influence
Development partners and funders Low High High Low Low
Academia Low Low High Low Low
Professionals and health workers Low Low Low High Medium
Civil society organisations/
Non-governmental organisations
Low Low Medium Low High
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Evidence and its use in the IMNCH strategy development
Various types of locally and internationally generated
evidence were said to be used in developing the IMNCH
strategy. The evidence broadly includes published arti-
cles, lessons from international experience, epidemio-
logical reports, stakeholder consultations, existing survey
reports, situation analysis and existing policy documents.
Although different groups of respondents acknowledged
specific types of evidence, three types of evidence,
namely (1) published research articles, particularly the
Lancet survival series, (2) survey reports and (3) situ-
ation analysis, appeared to be the recurring evidences in
most interviews. Following a stakeholder sensitization
on the need for the IMNCH strategy, a technical working
group was formed which held a series of meetings to
scope for and identify what evidence was in existence in
relation to maternal and child health. With financial as-
sistance from development partners, the evidences gath-
ered were disseminated to policymakers.
Actors’ perception of evidence and its use in developing
the IMNCH strategy
Different groups of actors had varied opinions of what
constitutes robust and appropriate evidence for policy.
While the policy elites and government officials felt that
documentation, comprehensiveness, representativeness
and proven effectiveness were enough to confer robust-
ness on available evidence, academics and professionals
would only characterize such information as robust evi-
dence if it was obtained through rigorous scientific re-
search/work. Development partners on the other hand
would describe evidence as robust if in addition to being
of proven effect, it provides clear guidance to decision
making. Supporting quotes are:
“Evidence is a documentation of something
that has proven effectiveness. [….] if you are
writing on a national document then you use
data that is representative of the whole country”
(Policymaker)
“Because they [Lancet] were publishing, they
had a comprehensive document. [….] it is
important that when you work that you have
the current information on whatever issue
you are working on.” (Government official)
“Evidence comes from properly designed randomized
control trials with appropriate conceptualization and
allocation”
These actors’ perceptions of what constitute robust
evidence can be seen to reflect on the types of evidence
they found useful for developing the IMNCH strategy
(Additional File: 1 TableS1). The policy elites and gov-
ernment officials mentioned all the listed types of evi-
dence as being useful for the process. For the three
groups of actors who found programme reports and les-
sons from experience useful, the ability of these types of
evidence to provide information concerning interven-
tions that have been proven to be effective was the basis
for their perceived usefulness. Published articles, on the
other hand, were very useful to professionals and aca-
demics for their scientific rigor, and to policy elites and
government officials because they are documented. The
situation analysis and DHS were also useful to two cat-
egories of actors for different reasons: for the policy
elites and government officials, they provide information
that is representative of the country/context; while for
the development partners and donors, they provide use-
ful information that guides decisions of resource alloca-
tion. The development partners’ group and the civil
society group also identified published articles as being
useful in the strategy development process, though the
reasons were not stated.
The development partners played a prominent role in
the generation and dissemination of types of evidence
that were used in developing the IMNCH strategy,
“WHO was … encouraging and promoting dissemination
of evidence” (Government official); and their roles in
funding the generation and dissemination of certain
types of evidence could count as the basis of their per-
ception of those types of evidence as useful for develop-
ing the IMNCH strategy: “A robust Situation Analysis
was supported by partners. We support generation of
DHS” (Development partner). There was the perception
that development partners are mostly driven by their
own agenda or self-set goals, which they would push for
regardless of its alignment with the country’s felt need:
“Often times the partners will have their own self set
goals that they want to achieve” (Policy elite). Duplica-
tion of efforts with resultant neglect of certain areas of
health need was stated as the consequence of having
different development partners working in parallel
without a well thought out plan for partner coordin-
ation by the government: “So often times you see dupli-
cation of efforts, […] while some other areas are
neglected. So if there could be a synergy where the
partners will be involved completely with the govern-
ment, [….] it will improve our system” (Policy elite).
The technical working group (comprising of technical
experts) appeared to have driven the process of identifying
and synthesizing relevant information: “It is the core work-
ing group that scopes for evidence and then synthesizes
them […] and identifies the ones to be selected” (Policy
elite). This group of experts is comprised of academics
and representatives of professional groups who provide
technical advice to policy elites on policy direction and
Mbachu et al. Health Research Policy and Systems  (2016) 14:27 Page 7 of 11
content. Their bias for scientific rigor contributes signifi-
cantly to what types of evidence get used in decision mak-
ing, as typified by the IMNCH strategy, where rigorous
research articles (systematic reviews) were used.
The government officials and policy elites are mandated
to use available evidences in developing the strategy. Their
role (or the limits of it) in evidence generation and dis-
semination could explain their perception of all the types
of evidence as useful. Their degree of perception of useful-
ness, however, can be seen to vary depending on the type
of evidence, and this could be attributed to the ease of
access of evidence types.
Contextual influences on actors’ preferences for and use
of evidence
National and international contextual factors influenced
actors’ preferences for and use of evidence in developing
the IMNCH strategy. Table 4 below highlights some of
the contextual factors and their influence/s on actors’
preferences for and use of evidence.
The Nigerian health system operates a federal struc-
ture with the three levels of operation – national, state
and local government – having autonomy to make deci-
sions and implement plans. However, health policy-
making is a prerogative of the national level and most
state policies in health are adapted from those made at
the national level. The political transition to democracy,
accompanied by an improvement in the budgetary allo-
cation to health, provided a window of opportunity to
scale-up high-impact interventions in maternal and child
health [12]. The strategy was developed within the frame-
work of the National Health Sector Reform Program to
address the most common conditions responsible for ma-
ternal and under-5 mortality in Nigeria.
The high maternal and child mortality rates, despite
numerous interventions in the country, pointed to the
need for a change in strategy and approach. The coun-
try’s slow progress towards attaining the MDG targets
for maternal and child health and a need for its activities
to align with the global movement, were perceived as
major contextual influences on the strategy develop-
ment: “We need to keep abreast of new guidelines, new
ways of providing support to maternal and child health;
we very much align with WHO, the benchmark” (CSO).
The choice of interventions to be included in the strat-
egy was influenced by the challenges of limited human,
financial and infrastructural resources in the country,
and the availability of evidence of low-cost high-impact
interventions that were promoted by development part-
ners. Most of the evidence-based interventions identified
at the global level were, according to the strategy docu-
ment, already being implemented in Nigeria. The major
problem, however, was that their coverage was low.
The marginal budgeting for bottlenecks approach was
promoted by the development partners and was used
to systematically identify health system constraints to
MCH and operational strategies for overcoming them.
This marginal budgeting for bottlenecks tool develop-
ment was funded by the development partners.
National level policymakers, on the other hand, were
tasked with the responsibility of producing a compre-
hensive plan of action for the recently developed Child
Health Policy, but also a strategy which in addition to
that will address the high maternal mortality indices.
They were therefore open to any type of evidence that
could support the policy and its implementation. How-
ever, they were constrained by the limited timeline to pro-
duce a strategy and this appears to have resulted in
Table 4 Perception of contextual influence on evidence use for the Integrated Maternal Newborn and Child Health (IMNCH) strategy
Contextual factors Influence on evidence use for developing the IMNCH strategy
Limited resources – finance, human, infrastructure Choice of evidence of low-cost interventions
Use of evidence that was promoted by funders of the strategy
development and aspects of its implementation
Poor coverage of maternal and child health (MCH) services,
health system constraints and operational challenges
Marginal budgeting for bottleneck approach was used to systematically
identify health system constraints to MCH and operational strategies
for overcoming them
Existing child health policy without a comprehensive plan of
action for implementation
Underpins the need for a strategy document
Preference for evidence that would support the policy and its
implementation
Need to align country’s activities to global movement Underpins the decision to develop the strategy
High (sustained) maternal and child mortality rates Underpin need for strategy change
High impact interventions
Slow progress towards attaining Millennium Development Goals 4 and
5
Underpins the choice of evidence of high-impact interventions
Limited time to produce strategy with Limited actor
engagement and information/evidence gathering
Preference for and use of already existing and easily accessible evidence
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limited actor engagement and information/evidence gath-
ering. As stated by a stakeholder: “we need to factor the
fact that stakeholders have other engagements, so enough
time …. will also help partners to articulate their own
inputs” (CSO).
Discussion
The breadth of evidence used in developing the IMNCH
strategy was wide and could be linked to the involve-
ment of various groups of actors at different stages of
the policy development. Although most evidence-to-
policy frameworks have focused on bridging the gap be-
tween researchers and policymakers [20, 21], it may be
helpful to broaden knowledge translation platforms to
include other types of actors in policy development [22].
Orem et al. [22], for instance, highlighted that policy-
makers were in support of the inclusion of other groups
of actors beyond researchers in evidence process for
policy development. However, they also recognize that
the contributions of these groups of actors has remained
largely unexplored [22]. Findings from our study and simi-
lar studies show that sound evidence-informed policies
require the inputs of different groups of actors, such as
CSOs and labour unions, whose roles are becoming in-
creasing noticeable in research priority setting and dis-
semination [22–25].
Different actors played different roles in developing
the IMNCH strategy as well as in generating, dissemin-
ating or using evidence for strategy development. Al-
though there is an overlap in the categories of actors
involved in the evidence process and strategy develop-
ment, some people played more prominent roles than
others. In Nigeria, like in most other countries, public
policymaking is the mandate of elected or appointed
government officials who are influenced by other actors
with diverse interests [26]. Evidence shows that active
participants (policy actors) in policy development in-
clude the government officials who have the mandate
to make policies, the legislators who approve these
policies, development partners who provide funding
and other non-state actors who represent personal or
group interests [27–31].
The capacity of these different actors to influence policy
is directly linked to the type and amount of influence they
possess [27, 28] and the balance of these influences. The
actors who wield stronger influence are more likely to get
their interests on the policy agenda and to back this up
with supporting evidence. In order for other actors to have
just as much influence, it has been suggested that health
policy networks be formed between weak and strong
actors to augment influence and bridge interests [31, 32].
Other groups of actors who may not have the power
to make or enforce policy themselves, exercise differ-
ent levels of influence that are determined by their
discretionary power in implementation or their lobby-
ing power [33, 34].
The degree of actors’ support for different types of evi-
dence for policymaking overlaps across actor categories,
and this was largely influenced by their roles in evidence
generation and/or dissemination and their participation
in policy development. Although characteristics of evi-
dence such as representation, completeness, availability
and timeliness influenced respondents’ perception of
best evidence for policy development, their roles in
generating and disseminating evidence determined what
types of evidence they preferred as useful for making the
IMNCH strategy. For instance, technical experts and
development partners who played key roles in the gener-
ation and dissemination of evidence of high-impact low-
cost interventions on MCH in the Lancet series, were of
the opinion that this was very useful for developing the
IMNCH strategy, whereas government officials leaned
more towards reports of expert consultations, which
they organized. Lehman and Gilson [35], in their study
of actor interfaces and practices of power in a commu-
nity health worker program, reported that actors react in
a positive way to their local realities and not necessarily
the agreed-on ‘best practice’; they are more likely to sup-
port what they understand would work. Hence, their in-
volvement (or lack of it) in the evidence process itself,
particularly in generating the evidence, contributes in a
major way to what evidence they would promote for
policy [36]. In addition, the type and level of influence
they have in policy development determines what type
of evidence gets used [34].
Other contextual factors, such as maternal and child
mortality rates, resource availability, coverage of MCH
services, existing related health policy, global targets and
time to develop policy affected actors’ decisions on evi-
dence use for developing the IMNCH strategy. The high
rates of maternal and child mortality in Nigeria informed
actors’ preference for the Demographic Health Survey
that reported these rates. The inadequacy of human re-
sources for health and limited government expenditure
on health in the country led to the decision to include
evidence of low-cost high-impact interventions in MCH
that have been applied in similar contexts. The strategy
document was developed just before the MDGs mid-term
review when it became clear that Nigeria was making very
slow progress and was unlikely to meet the targets of
MDGs 4 and 5 and time was of essence. This underpinned
the decision to use already existing evidence, rather than
implement and evaluate pilot interventions, as well as the
decision to use evidence of low-cost high-impact interven-
tions. Contextual factors present policymakers with op-
tions of how much (breadth and depth) and how well
evidence can be used to make policies [37]. It also pre-
sents an opportunity for them to manoeuvre towards
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accomplishing their goals [28, 38], which in this case was
to develop a strategy document within a short time frame.
The scope of this study only allows us to make infer-
ences about the contributions of the range of actors to
evidence use in policymaking. It would be useful to
explore the extent to which actors’ contributions of evi-
dence informed policy development by also examining
policy implementation; this would also allow us to ob-
jectively assess whether the evidence used was helpful
for achieving the goal of the strategy.
Conclusions
Contributors of evidence who also have the power to
influence the decision-making process are better posi-
tioned to determine the types of evidence that eventually
get used in policy and strategy development. The value
in having different groups of actors contribute to evidence
use in policymaking is that different types of useful evi-
dence are identified, and policymakers have as much in-
formation as is possible for decision making. Government
officials, who have the mandate to make policies within a
range of contexts, are also expected to involve and coord-
inate as many stakeholders as possible in the process.
They must, therefore, pay attention to the fact that actors
are driven by contextual factors in their local realities, in-
terests and experiences, even when it concerns evidence-
informed policymaking, and all of these peculiarities need
to be managed.
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